TXH11106: A Third-Generation MreB Inhibitor with Enhanced Activity against a Broad Range of Gram-Negative Bacterial Pathogens

The emergence of multi-drug-resistant Gram-negative pathogens highlights an urgent clinical need to explore and develop new antibiotics with novel antibacterial targets. MreB is a promising antibacterial target that functions as an essential elongasome protein in most Gram-negative bacterial rods. Here, we describe a third-generation MreB inhibitor (TXH11106) with enhanced bactericidal activity versus the Gram-negative pathogens Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa compared to the first- and second-generation compounds A22 and CBR-4830, respectively. Large inocula of these four pathogens are associated with a low frequency of resistance (FOR) to TXH11106. The enhanced bactericidal activity of TXH11106 relative to A22 and CBR-4830 correlates with a correspondingly enhanced capacity to inhibit E. coli MreB ATPase activity via a noncompetitive mechanism. Morphological changes induced by TXH11106 in E. coli, K. pneumoniae, A. baumannii, and P. aeruginosa provide further evidence supporting MreB as the bactericidal target of the compound. Taken together, our results highlight the potential of TXH11106 as an MreB inhibitor with activity against a broad spectrum of Gram-negative bacterial pathogens of acute clinical importance.

[1]  G. Panos,et al.  Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions , 2021, Antibiotics.

[2]  Ting Li,et al.  Recent progress of bacterial FtsZ inhibitors with a focus on peptides , 2020, The FEBS journal.

[3]  R. Karaman,et al.  Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It , 2020, Molecules.

[4]  Elvis Awuni.  Status of Targeting MreB for the Development of Antibiotics , 2020, Frontiers in Chemistry.

[5]  Antibiotic resistance threats in the United States, 2019 , 2019 .

[6]  John A. Robinson,et al.  Chimeric peptidomimetic antibiotics against Gram-negative bacteria , 2019, Nature.

[7]  T. M. Belete.  Novel targets to develop new antibacterial agents and novel alternatives to antibacterial agents , 2019, Human Microbiome Journal.

[8]  Wei Wang,et al.  Antibiotic resistance: a rundown of a global crisis , 2018, Infection and drug resistance.

[9]  S. Saigal,et al.  Action and resistance mechanisms of antibiotics: A guide for clinicians , 2017, Journal of anaesthesiology, clinical pharmacology.

[10]  M. Sagrillo,et al.  Antibacterial, cyto and genotoxic activities of A22 compound ((S-3, 4 -dichlorobenzyl) isothiourea hydrochloride). , 2016, Microbial pathogenesis.

[11]  D. Pieper,et al.  Tackling Threats and Future Problems of Multidrug-Resistant Bacteria. , 2016, Current topics in microbiology and immunology.

[12]  C. L. Ventola.  The antibiotic resistance crisis: part 1: causes and threats. , 2015, P & T : a peer-reviewed journal for formulary management.

[13]  T. Bharat,et al.  Bacterial actin MreB forms antiparallel double filaments , 2014, eLife.

[14]  E. LaVoie,et al.  Pharmacokinetics and in vivo antistaphylococcal efficacy of TXY541, a 1-methylpiperidine-4-carboxamide prodrug of PC190723. , 2013, Biochemical pharmacology.

[15]  The antibiotic alarm , 2013, Nature.

[16]  Marten Postma,et al.  Colocalization and interaction between elongasome and divisome during a preparative cell division phase in Escherichia coli , 2013, Molecular microbiology.

[17]  M. Fujisawa,et al.  Clinical investigation of isolated bacteria from urinary tracts of hospitalized patients and their susceptibilities to antibiotics , 2009, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[18]  M. de Pedro,et al.  Morphogenesis of rod-shaped sacculi. , 2008, FEMS microbiology reviews.

[19]  M. Hacker,et al.  Pharmacology: Principles and Practice , 2008 .

[20]  G. Robertson,et al.  A Novel Indole Compound That Inhibits Pseudomonas aeruginosa Growth by Targeting MreB Is a Substrate for MexAB-OprM , 2007, Journal of bacteriology.

[21]  J. Gober,et al.  MreB, the cell shape‐determining bacterial actin homologue, co‐ordinates cell wall morphogenesis in Caulobacter crescentus , 2004, Molecular microbiology.

[22]  K. Nagai,et al.  Novel S-Benzylisothiourea Compound That Induces Spherical Cells in Escherichia coli Probably by Acting on a Rod-shape-determining Protein(s) Other Than Penicillin-binding Protein 2 , 2002, Bioscience, biotechnology, and biochemistry.

[23]  Jan Löwe,et al.  Prokaryotic origin of the actin cytoskeleton , 2001, Nature.

[24]  J. Hurley.  The sugar kinase/heat shock protein 70/actin superfamily: implications of conserved structure for mechanism. , 1996, Annual review of biophysics and biomolecular structure.

[25]  S. Tamaki,et al.  Mutant isolation and molecular cloning of mre genes, which determine cell shape, sensitivity to mecillinam, and amount of penicillin-binding proteins in Escherichia coli , 1987, Journal of bacteriology.

[26]  S. Normark.  Mutation in Escherichia coli K-12 Mediating Spherelike Envelopes and Changed Tolerance to Ultraviolet Irradiation and Some Antibiotics , 1969, Journal of bacteriology.